These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2380017)

  • 1. A phase I and pharmacokinetic study of intravenous vinzolidine.
    Taylor CW; Salmon SE; Satterlee WG; Robertone AB; McCloskey TM; Holdsworth MT; Plezia PM; Alberts DS
    Invest New Drugs; 1990; 8 Suppl 1():S51-7. PubMed ID: 2380017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors.
    Takasugi BJ; Robertone AB; Salmon SE; Jones SE; Alberts DS
    Invest New Drugs; 1984; 2(4):387-90. PubMed ID: 6096287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule.
    Budman DR; Kreis W; Behr J; Schulman P; Lichtman S; Allen SL; Weiselberg L; Satterlee WG; Nelson RL; Vinciguerra V
    Invest New Drugs; 1990 Aug; 8(3):269-74. PubMed ID: 2272767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma.
    Takasugi BJ; Jones SE; Robertone AB
    Cancer Treat Rep; 1984 Nov; 68(11):1399-401. PubMed ID: 6498855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of vinzolidine.
    Budman DR; Schulman P; Marks M; Vinciguerra V; Weiselberg L; Kreis W; Degnan TJ
    Cancer Treat Rep; 1984; 68(7-8):979-82. PubMed ID: 6744350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors.
    Lorusso PM; Edelman MJ; Bever SL; Forman KM; Pilat M; Quinn MF; Li J; Heath EI; Malburg LM; Klein PJ; Leamon CP; Messmann RA; Sausville EA
    J Clin Oncol; 2012 Nov; 30(32):4011-6. PubMed ID: 23032618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of intravenously injected tritiated vinzolidine.
    Kreis W; Budman DR; Freeman J; Bergstrom RF; Nelson RL
    Cancer Chemother Pharmacol; 1990; 26(6):419-22. PubMed ID: 2225313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of a new vinca alkaloid derivative, S12363, in advanced breast cancer.
    Adenis A; Pion JM; Fumoleau P; Pouillart P; Marty M; Giroux B; Bonneterre J
    Cancer Chemother Pharmacol; 1995; 35(6):527-8. PubMed ID: 7882462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of vindesine in patients with advanced cancer.
    Currie VE; Wong PP; Krakoff IH; Young CW
    Cancer Treat Rep; 1978 Sep; 62(9):1333-6. PubMed ID: 356986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum.
    Sarna G; Mitsuyasu R; Figlin R; Ambersley J; Groopman J
    Cancer Chemother Pharmacol; 1985; 14(1):12-4. PubMed ID: 3965155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
    Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
    Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
    Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
    Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.
    Fyfe D; Price C; Langley RE; Pagonis C; Houghton J; Osborne L; Woll PJ; Gardner C; Baguley BC; Carmichael J;
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):333-7. PubMed ID: 11345650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of vintriptol, a tryptophan ester of vinblastine.
    Oosterkamp HM; Vlasveld LT; Wanders J; Beijnen JH; van Tellingen O; Dubbelman AC; Simonetti GP; Franklin HR; Vermorken JB; Ten Bokkel Huinink WW
    Eur J Cancer; 1991; 27(10):1222-6. PubMed ID: 1835590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.